Catalent pledges to increase production of Moderna vaccine at its Indiana fill-finish plant
One of the big contract partners in the Covid-19 effort, Catalent has signed deals with most of the major vaccine players to help ramp up supply. Now, the New Jersey firm will expand its deal with Moderna in hopes of churning out double the amount of finished vials in time for summer.
The CDMO will increase its production capacity of the vaccine in its Bloomington, IN biologics facility through its new high-speed vial filling line, Catalent announced Tuesday. Sources close to the matter told The Wall Street Journal that agreement will increase the vaccine output in April to 400 vials a minute.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.